Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential

KL Nowak, K Hopp - Clinical Journal of the American Society of …, 2020 - journals.lww.com
Autosomal dominant polycystic kidney disease is characterized by progressive development
and enlargement of kidney cysts, leading to ESKD. Because the kidneys are under high …

[HTML][HTML] Ketosis ameliorates renal cyst growth in polycystic kidney disease

JA Torres, SL Kruger, C Broderick, T Amarlkhagva… - Cell metabolism, 2019 - cell.com
Mild reduction in food intake was recently shown to slow polycystic kidney disease (PKD)
progression in mouse models, but whether the effect was due to solely reduced calories or …

Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers

I Sorić Hosman, A Cvitković Roić, M Fištrek Prlić… - Frontiers in …, 2023 - frontiersin.org
Autosomal dominant polycystic kidney disease (ADPKD) is one of the leading causes of end-
stage renal disease. In spite of the recent tremendous progress in the understanding of …

Ketogenic dietary interventions in autosomal dominant polycystic kidney disease—a retrospective case series study: first insights into feasibility, safety and effects

S Strubl, S Oehm, JA Torres, F Grundmann… - Clinical kidney …, 2022 - academic.oup.com
Background Our laboratory published the first evidence that nutritional ketosis, induced by a
ketogenic diet (KD) or time-restricted diet (TRD), ameliorates disease progression in …

Combining metformin and drug-loaded kidney-targeting micelles for polycystic kidney disease

K Jiang, Y Huang, EJ Chung - Cellular and Molecular Bioengineering, 2023 - Springer
Introduction Autosomal dominant polycystic kidney disease (ADPKD) is the most common
inherited kidney disease that leads to eventual renal failure. Metformin (MET), an AMP …

mTOR and S6K1 drive polycystic kidney by the control of Afadin-dependent oriented cell division

M Bonucci, N Kuperwasser, S Barbe, V Koka… - Nature …, 2020 - nature.com
Abstract mTOR activation is essential and sufficient to cause polycystic kidneys in Tuberous
Sclerosis Complex (TSC) and other genetic disorders. In disease models, a sharp increase …

Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles

TB Malas, WN Leonhard, H Bange, Z Granchi… - …, 2020 - thelancet.com
Abstract Background Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the
most common causes of end-stage renal failure, caused by mutations in PKD1 or PKD2 …

Diet and Physical Activity in Adult Dominant Polycystic Kidney Disease: A Review of the Literature

I Capelli, S Lerario, V Aiello, M Provenzano… - Nutrients, 2023 - mdpi.com
Autosomal polycystic kidney disease is the most common inherited kidney disease
determining 5% of all end-stage kidney disease. The only therapy approved for this …

Ppia is the most stable housekeeping gene for qRT-PCR normalization in kidneys of three Pkd1-deficient mouse models

JJ Muñoz, AC Anauate, AG Amaral, FM Ferreira… - Scientific Reports, 2021 - nature.com
Abstract Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common
inherited renal disorder, characterized by renal cyst development leading to end-stage renal …

STAT signaling in polycystic kidney disease

S Strubl, JA Torres, AK Spindt, H Pellegrini, MC Liebau… - Cellular signalling, 2020 - Elsevier
The most common form of polycystic kidney disease (PKD) in humans is caused by
mutations in the PKD1 gene coding for polycystin1 (PC1). Among the many identified or …